These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 34185763

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
    Hong AR, Yoon JH, Kim HK, Kang HC.
    Front Endocrinol (Lausanne); 2020; 11():14. PubMed ID: 32047478
    [Abstract] [Full Text] [Related]

  • 4. Pembrolizumab-Induced Diabetes Mellitus Presenting as Diabetic Ketoacidosis in a Patient With Metastatic Colonic Adenocarcinoma.
    Kichloo A, Albosta MS, McMahon S, Movsesian K, Wani F, Jamal SM, Aljadah M, Singh J.
    J Investig Med High Impact Case Rep; 2020; 8():2324709620951339. PubMed ID: 32830561
    [Abstract] [Full Text] [Related]

  • 5. Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.
    Zezza M, Kosinski C, Mekoguem C, Marino L, Chtioui H, Pitteloud N, Lamine F.
    BMC Endocr Disord; 2019 Dec 23; 19(1):144. PubMed ID: 31870373
    [Abstract] [Full Text] [Related]

  • 6. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
    Clotman K, Janssens K, Specenier P, Weets I, De Block CEM.
    J Clin Endocrinol Metab; 2018 Sep 01; 103(9):3144-3154. PubMed ID: 29955867
    [Abstract] [Full Text] [Related]

  • 7. New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer.
    Cunha C, Silva E, Vieira AC, Saraiva C, Duarte S.
    Endocrinol Diabetes Metab Case Rep; 2022 Feb 01; 2022():. PubMed ID: 35140188
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Diabetic ketoacidosis induced by a single dose of pembrolizumab.
    Maamari J, Yeung SJ, Chaftari PS.
    Am J Emerg Med; 2019 Feb 01; 37(2):376.e1-376.e2. PubMed ID: 30361152
    [Abstract] [Full Text] [Related]

  • 10. A case of pembrolizumab-induced fulminant Type 1 diabetes mellitus in breast cancer.
    Tang Y, Zhao Z, Wang X, Zuo W, Zhang B, Yuan T, Fu Y.
    Immunotherapy; 2021 Apr 01; 13(6):483-489. PubMed ID: 33626915
    [Abstract] [Full Text] [Related]

  • 11. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma.
    Changizzadeh PN, Mukkamalla SKR, Armenio VA.
    J Immunother Cancer; 2017 Dec 19; 5(1):97. PubMed ID: 29254501
    [Abstract] [Full Text] [Related]

  • 12. Immune checkpoint inhibitor-induced diabetes mellitus with pembrolizumab.
    Zand Irani A, Almuwais A, Gibbons H.
    BMJ Case Rep; 2022 Jan 17; 15(1):. PubMed ID: 35039353
    [Abstract] [Full Text] [Related]

  • 13. Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report.
    Li S, Zhang Y, Sun Z, Hu J, Fang C.
    Medicine (Baltimore); 2018 Nov 17; 97(45):e12907. PubMed ID: 30407284
    [Abstract] [Full Text] [Related]

  • 14. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L, Zou X, Chen Y, Bai X, Liang T.
    Front Immunol; 2020 Nov 17; 11():2076. PubMed ID: 32973816
    [Abstract] [Full Text] [Related]

  • 15. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.
    de Filette JMK, Pen JJ, Decoster L, Vissers T, Bravenboer B, Van der Auwera BJ, Gorus FK, Roep BO, Aspeslagh S, Neyns B, Velkeniers B, Kharagjitsingh AV.
    Eur J Endocrinol; 2019 Sep 17; 181(3):363-374. PubMed ID: 31330498
    [Abstract] [Full Text] [Related]

  • 16. PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity.
    Akturk HK, Alkanani A, Zhao Z, Yu L, Michels AW.
    J Clin Endocrinol Metab; 2018 Oct 01; 103(10):3589-3592. PubMed ID: 30124874
    [Abstract] [Full Text] [Related]

  • 17. Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy - A comprehensive cancer center experience.
    Zhang Z, Sharma R, Hamad L, Riebandt G, Attwood K.
    Diabetes Res Clin Pract; 2023 Aug 01; 202():110776. PubMed ID: 37311494
    [Abstract] [Full Text] [Related]

  • 18. Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report.
    Porntharukchareon T, Tontivuthikul B, Sintawichai N, Srichomkwun P.
    J Med Case Rep; 2020 Sep 29; 14(1):171. PubMed ID: 32988414
    [Abstract] [Full Text] [Related]

  • 19. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
    Beck TN, Kudinov AE, Dulaimi E, Boumber Y.
    BMC Cancer; 2019 Apr 24; 19(1):379. PubMed ID: 31018834
    [Abstract] [Full Text] [Related]

  • 20. New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.
    Delasos L, Bazewicz C, Sliwinska A, Lia NL, Vredenburgh J.
    J Oncol Pharm Pract; 2021 Apr 24; 27(3):716-721. PubMed ID: 32723064
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.